Oklo's Groves Test Reactor Clears Final DOE Safety Hurdle, But Commercial Aurora Remains Unpaved

What happened

The DOE approved the Documented Safety Analysis for Oklo's Groves Isotope Test Reactor, the final safety basis needed to support startup, advancing the project toward operational authorization under the DOE's Reactor Pilot Program. This milestone follows the earlier PDSA approval for the Aurora powerhouse at INL, but applies specifically to the smaller Groves reactor used for isotope production, not Oklo's commercial 15-75 MWe Aurora units. While the DSA approval demonstrates regulatory progress and validates Oklo's safety design, it does not directly address the key thesis-breaking items the DeepValue report highlights: binding PPAs, definitive fuel contracts, and NRC licensing for the Aurora. The master report rates OKLO a WAIT with a base case of $55, emphasizing that the next 6-12 months require conversion of non-binding customer and fuel arrangements before the stock can be underwritten. With the stock at $51, this news may provide near-term sentiment support, but the fundamental gap between regulatory milestones and bankable commercial agreements remains.

Implication

The DSA approval for the Groves test reactor is a tangible regulatory win that may buoy the stock, but it does not change the core thesis that OKLO needs enforceable commercial contracts and NRC licensing for its Aurora product to justify the current valuation. The DeepValue report flags that the company's customer engagements remain non-binding LOIs and the Meta deal is a prepayment mechanism, not a PPA. Until those convert, the stock remains a headline-driven option on regulatory progress rather than a cash-flow backed investment. We reiterate the WAIT rating and attractive entry at $40, with a trim above $75.

Thesis delta

This news positively impacts the regulatory timeline for the Groves reactor, but does not shift the two thesis breakers: lack of binding PPAs and definitive fuel contracts. The probability of the base case (regulatory clarity) increases slightly, but the bear case risks (capital availability, non-binding commercial posture) remain unchanged. Therefore, the rating stays WAIT as the market has already priced in regulatory progress, and the next catalysts are still commercial and NRC-based.